Early lung cancer drug combo trial halted after just 6 patients
NCT ID NCT04638582
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at giving the immunotherapy drug pembrolizumab (Keytruda) alone or with chemotherapy before surgery for people with early-stage non-small cell lung cancer. The goal was to see if these treatments could shrink tumors and improve outcomes. However, the trial was stopped early and only enrolled 6 participants, so results are very limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER, NONSMALL CELL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
McGill University Health Center
Montreal, Quebec, H4A3J1, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood test could reveal how lung cancer evolves during treatment
- Scientists probe how lung cancer outsmarts key drugs
- Blood test could guide who needs extra cancer therapy after lung surgery
- Tiny study probes risks of lung cancer combo therapy
- Blood markers may reveal which lung cancer patients stay Cancer-Free after treatment
- Lung cancer combo trial halted early – what we know